Literature DB >> 7283294

Clinical features of types A and B food-borne botulism.

J M Hughes, J R Blumenthal, M H Merson, G L Lombard, V R Dowell, E J Gangarosa.   

Abstract

Medical records of 55 patients with type A and type B food-borne botulism reported to the Centers for Disease Control during 2 years were reviewed to assess the clinical features and severity of illness, diagnostic test results, nature of complications, amd causes of death. Some patients had features not usually associated with botulism including paresthesia (14%), asymmetric extremely weakness (17%), asymmetric ptosis (8%), slightly elevated cerebrospinal fluid protein values (14%), and positive responses to edrophonium chloride(26%). Several observation suggest that type A was more severe than type B disease. Although the case-fatality ratio was not significantly greater, patients with type A disease saw a physician earlier in the course of illness, were more likely to need ventilatory support, and were hospitalized longer. Patients who died were older than those who survived. Deaths within the first 2 weeks resulted from failure to recognized the severity of the disease or from pulmonary or systemic infection whereas the three late deaths were related to respirator malfunction.

Entities:  

Mesh:

Year:  1981        PMID: 7283294     DOI: 10.7326/0003-4819-95-4-442

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  32 in total

Review 1.  Botulism: a potentially common problem.

Authors:  J M Shneerson
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

Review 2.  Evidence for the effectiveness of botulinum toxin for sialorrhoea.

Authors:  D D Truong; R Bhidayasiri
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

Review 3.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

4.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

Review 5.  Botulinum toxin. From poison to medicine.

Authors:  L E Davis
Journal:  West J Med       Date:  1993-01

Review 6.  Acute neuromuscular respiratory paralysis.

Authors:  R A Hughes; D Bihari
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

7.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

Review 8.  Physical assessment and differential diagnosis of the poisoned patient.

Authors:  K R Olson; P R Pentel; M T Kelley
Journal:  Med Toxicol       Date:  1987 Jan-Feb

9.  Oral toxicities of Clostridium botulinum type A and B toxins from different strains.

Authors:  I Ohishi
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Wound botulism in injection drug users: time to antitoxin correlates with intensive care unit length of stay.

Authors:  Steven R Offerman; Melissa Schaefer; Joseph G Thundiyil; Matthew D Cook; James F Holmes
Journal:  West J Emerg Med       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.